Compare Amgen, Inc. (AMGN) vs 3M Company (MMM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs 3M Company — how do they compare? Amgen, Inc. trades at $356.51 (market cap $196.12B), while 3M Company trades at $156.96 (market cap $82.16B). The key difference: Amgen, Inc. is far larger — about 2.4× 3M Company's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | MMM | |
|---|---|---|
Market Cap | $196.12B | $82.16B |
Sector | Health | Industrials |
52-Week High | $388.16 | $174.61 |
52-Week Low | $271.18 | $141.10 |
Enterprise Value | $241.41B | $90.56B |
Dividend Yield | 2.77% | 1.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
3M (MMM) trades at $157.52, up 1.4% today, with a bearish technical signal despite recent earnings beats. The company shows strong profitability with a 72.14% ROE and 13.03% net margin, though revenue has declined from 2022 peaks. Recent news highlights segment weakness in Consumer but strength in Safety & Industrial, alongside strategic partnerships like the Airbus A220 supply agreement.
Outlook is mixed: analyst consensus is cautious with a $148.75 price target below current levels, citing persistent consumer segment challenges. Investment appeal lies in dividend yield and cost optimization efforts, but risks include revenue stagnation and high debt levels. The stock faces headwinds from technical bearishness and modest growth projections.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About 3M Company
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →
